ITCI Intra-Cellular Therapies Inc

For the fiscal year ended 31/12/2022: Intra-Cellular Therapies Inc's revenues increased by 198.69% and amounted to 250.31M. Net income increased by 9.81% to -256.26M. Net assets increased by 57.00% to 656.07M and EPS increased from -3.50 to -2.72.